Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of V920 Ebola vaccine in HIV-infected adults and adolescents
2016-004853-34Phase 2
- Sponsor
- Dalhousie University
- Start
- May 2017
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Ebola virus disease (EVD) comparing V920 vaccine with Placebo (2 arms). Primary endpoint: Number of adverse events following V920 vaccination.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on 2016-004853-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004853-34.